Compare NTLA & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | VET |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2016 | 2004 |
| Metric | NTLA | VET |
|---|---|---|
| Price | $11.15 | $14.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 7 |
| Target Price | ★ $23.11 | $15.17 |
| AVG Volume (30 Days) | ★ 5.0M | 1.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 2.88% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | $22.90 |
| Revenue Next Year | $143.36 | $8.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $7.21 |
| 52 Week High | $18.48 | $14.82 |
| Indicator | NTLA | VET |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 72.89 |
| Support Level | $10.15 | $11.16 |
| Resistance Level | $13.50 | $14.28 |
| Average True Range (ATR) | 0.76 | 0.47 |
| MACD | -0.09 | 0.21 |
| Stochastic Oscillator | 20.26 | 85.96 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.